Assessing Health and Economic Outcomes William C. Black, M.D. Director ACRIN Outcomes & Economics...
-
Upload
edwin-simon -
Category
Documents
-
view
215 -
download
0
Transcript of Assessing Health and Economic Outcomes William C. Black, M.D. Director ACRIN Outcomes & Economics...
![Page 1: Assessing Health and Economic Outcomes William C. Black, M.D. Director ACRIN Outcomes & Economics Core Laboratory Dartmouth-Hitchcock Medical Center.](https://reader035.fdocuments.us/reader035/viewer/2022062516/56649daf5503460f94a9ce0c/html5/thumbnails/1.jpg)
Assessing Health
and Economic
Outcomes William C. Black, M.D.
Director ACRIN Outcomes & Economics Core
Laboratory
Dartmouth-Hitchcock Medical Center
![Page 2: Assessing Health and Economic Outcomes William C. Black, M.D. Director ACRIN Outcomes & Economics Core Laboratory Dartmouth-Hitchcock Medical Center.](https://reader035.fdocuments.us/reader035/viewer/2022062516/56649daf5503460f94a9ce0c/html5/thumbnails/2.jpg)
Outline
• Background
• Health outcomes
• Economic outcomes
• Cost-Effectiveness
Analysis
![Page 3: Assessing Health and Economic Outcomes William C. Black, M.D. Director ACRIN Outcomes & Economics Core Laboratory Dartmouth-Hitchcock Medical Center.](https://reader035.fdocuments.us/reader035/viewer/2022062516/56649daf5503460f94a9ce0c/html5/thumbnails/3.jpg)
“Outcomes”
• Geography is destiny
• More is not better
• Patient preferences
matter
![Page 4: Assessing Health and Economic Outcomes William C. Black, M.D. Director ACRIN Outcomes & Economics Core Laboratory Dartmouth-Hitchcock Medical Center.](https://reader035.fdocuments.us/reader035/viewer/2022062516/56649daf5503460f94a9ce0c/html5/thumbnails/4.jpg)
http://www.cms.hhs.gov/NationalHealthExpendData/02_NationalHealthAccountsHistorical.asp#TopOfPage
US Health Care Expenditures
1960 1965 1970 1975 1980 1985 1990 1995 2000 2005 2010$0.00
$0.50
$1.00
$1.50
$2.00
$2.50
Year
Tri
llio
ns
![Page 5: Assessing Health and Economic Outcomes William C. Black, M.D. Director ACRIN Outcomes & Economics Core Laboratory Dartmouth-Hitchcock Medical Center.](https://reader035.fdocuments.us/reader035/viewer/2022062516/56649daf5503460f94a9ce0c/html5/thumbnails/5.jpg)
Health Expenditures by Country, 2006
![Page 6: Assessing Health and Economic Outcomes William C. Black, M.D. Director ACRIN Outcomes & Economics Core Laboratory Dartmouth-Hitchcock Medical Center.](https://reader035.fdocuments.us/reader035/viewer/2022062516/56649daf5503460f94a9ce0c/html5/thumbnails/6.jpg)
Life Expectancy by Country
Country Life Exp Rank
Macau 84.4 1
Japan 82.1 3
Canada 81.2 7
United Kingdom 79.0 36
United States 78.1 49
Mexico 76.1 71
China 73.5 108
Iraq 70.0 145
![Page 7: Assessing Health and Economic Outcomes William C. Black, M.D. Director ACRIN Outcomes & Economics Core Laboratory Dartmouth-Hitchcock Medical Center.](https://reader035.fdocuments.us/reader035/viewer/2022062516/56649daf5503460f94a9ce0c/html5/thumbnails/7.jpg)
Growth in physician services
![Page 8: Assessing Health and Economic Outcomes William C. Black, M.D. Director ACRIN Outcomes & Economics Core Laboratory Dartmouth-Hitchcock Medical Center.](https://reader035.fdocuments.us/reader035/viewer/2022062516/56649daf5503460f94a9ce0c/html5/thumbnails/8.jpg)
“Outcomes”
• Determine what
works
• Assess pt preferences
• Deliver appropriate
care
![Page 9: Assessing Health and Economic Outcomes William C. Black, M.D. Director ACRIN Outcomes & Economics Core Laboratory Dartmouth-Hitchcock Medical Center.](https://reader035.fdocuments.us/reader035/viewer/2022062516/56649daf5503460f94a9ce0c/html5/thumbnails/9.jpg)
Hierarchical Model of EfficacyLevel 1. Technical
Level 2. Diagnostic accuracyLevel 3. Diagnostic thinkingLevel 4. TherapeuticLevel 5. Patient outcomeLevel 6. Societal
Fryback & Thornbury. Medical Decision Making 1991;11:88-94.
![Page 10: Assessing Health and Economic Outcomes William C. Black, M.D. Director ACRIN Outcomes & Economics Core Laboratory Dartmouth-Hitchcock Medical Center.](https://reader035.fdocuments.us/reader035/viewer/2022062516/56649daf5503460f94a9ce0c/html5/thumbnails/10.jpg)
Accuracy
• SE = Pr(T+| D+)
• SP = Pr(T-| D-)
• Az = Area under ROC
curve
![Page 11: Assessing Health and Economic Outcomes William C. Black, M.D. Director ACRIN Outcomes & Economics Core Laboratory Dartmouth-Hitchcock Medical Center.](https://reader035.fdocuments.us/reader035/viewer/2022062516/56649daf5503460f94a9ce0c/html5/thumbnails/11.jpg)
Disease
PLE D + B
No disease
1-PLE N -C
Treat
Test positive
SELE D + B
Test negative
1-SELE D
Disease
P
Test positive
1-SPLE N -C
Test negative
SPLE N
No disease
1-P
Test
Disease
PLE D
No disease
1-PLE N
No Treat
CHOOSE
![Page 12: Assessing Health and Economic Outcomes William C. Black, M.D. Director ACRIN Outcomes & Economics Core Laboratory Dartmouth-Hitchcock Medical Center.](https://reader035.fdocuments.us/reader035/viewer/2022062516/56649daf5503460f94a9ce0c/html5/thumbnails/12.jpg)
Baseline Values
P 0.5
B, C 1.0
LEN 2.0
LED 0.0
SE, SP 0.8
![Page 13: Assessing Health and Economic Outcomes William C. Black, M.D. Director ACRIN Outcomes & Economics Core Laboratory Dartmouth-Hitchcock Medical Center.](https://reader035.fdocuments.us/reader035/viewer/2022062516/56649daf5503460f94a9ce0c/html5/thumbnails/13.jpg)
Expected Utility
Treat 1.0Test 1.3No Treat 1.0
![Page 14: Assessing Health and Economic Outcomes William C. Black, M.D. Director ACRIN Outcomes & Economics Core Laboratory Dartmouth-Hitchcock Medical Center.](https://reader035.fdocuments.us/reader035/viewer/2022062516/56649daf5503460f94a9ce0c/html5/thumbnails/14.jpg)
Limitations
• Disease spectrum
• Accuracy of test
• Natural History of dz
• Effectiveness of
treatment
![Page 15: Assessing Health and Economic Outcomes William C. Black, M.D. Director ACRIN Outcomes & Economics Core Laboratory Dartmouth-Hitchcock Medical Center.](https://reader035.fdocuments.us/reader035/viewer/2022062516/56649daf5503460f94a9ce0c/html5/thumbnails/15.jpg)
Randomized Clinical Trial
To ensure that observed
differences in
outcome depend only on the
interven-
tions under investigation and
not on
other factors that affect
outcome.
![Page 16: Assessing Health and Economic Outcomes William C. Black, M.D. Director ACRIN Outcomes & Economics Core Laboratory Dartmouth-Hitchcock Medical Center.](https://reader035.fdocuments.us/reader035/viewer/2022062516/56649daf5503460f94a9ce0c/html5/thumbnails/16.jpg)
Outcomes & Economic Core Lab
• Measure Health Related QOL
• Measure costs
• Analyze cost-effectiveness
![Page 17: Assessing Health and Economic Outcomes William C. Black, M.D. Director ACRIN Outcomes & Economics Core Laboratory Dartmouth-Hitchcock Medical Center.](https://reader035.fdocuments.us/reader035/viewer/2022062516/56649daf5503460f94a9ce0c/html5/thumbnails/17.jpg)
Health Related QOL
• Global rating
• Symptoms
• Functional status
![Page 18: Assessing Health and Economic Outcomes William C. Black, M.D. Director ACRIN Outcomes & Economics Core Laboratory Dartmouth-Hitchcock Medical Center.](https://reader035.fdocuments.us/reader035/viewer/2022062516/56649daf5503460f94a9ce0c/html5/thumbnails/18.jpg)
Health Related QOL
• Non-preference based
– Generic, e.g., EVGFP, SF-36
– Disease-specific, SAQ
• Preference based
– Direct, e.g., VAS
– Indirect, e.g., SF-6D
![Page 19: Assessing Health and Economic Outcomes William C. Black, M.D. Director ACRIN Outcomes & Economics Core Laboratory Dartmouth-Hitchcock Medical Center.](https://reader035.fdocuments.us/reader035/viewer/2022062516/56649daf5503460f94a9ce0c/html5/thumbnails/19.jpg)
![Page 20: Assessing Health and Economic Outcomes William C. Black, M.D. Director ACRIN Outcomes & Economics Core Laboratory Dartmouth-Hitchcock Medical Center.](https://reader035.fdocuments.us/reader035/viewer/2022062516/56649daf5503460f94a9ce0c/html5/thumbnails/20.jpg)
Measuring Preferences - Direct
• Rating scale
• Standard gamble
• Time-tradeoff
![Page 21: Assessing Health and Economic Outcomes William C. Black, M.D. Director ACRIN Outcomes & Economics Core Laboratory Dartmouth-Hitchcock Medical Center.](https://reader035.fdocuments.us/reader035/viewer/2022062516/56649daf5503460f94a9ce0c/html5/thumbnails/21.jpg)
Visual Analogue Scale
![Page 22: Assessing Health and Economic Outcomes William C. Black, M.D. Director ACRIN Outcomes & Economics Core Laboratory Dartmouth-Hitchcock Medical Center.](https://reader035.fdocuments.us/reader035/viewer/2022062516/56649daf5503460f94a9ce0c/html5/thumbnails/22.jpg)
Standard Gamble
![Page 23: Assessing Health and Economic Outcomes William C. Black, M.D. Director ACRIN Outcomes & Economics Core Laboratory Dartmouth-Hitchcock Medical Center.](https://reader035.fdocuments.us/reader035/viewer/2022062516/56649daf5503460f94a9ce0c/html5/thumbnails/23.jpg)
Measuring Preferences - Indirect
• Quality of Well Being
• Health utilities index
• EuroQoL-5D
• Short Form -6D
![Page 24: Assessing Health and Economic Outcomes William C. Black, M.D. Director ACRIN Outcomes & Economics Core Laboratory Dartmouth-Hitchcock Medical Center.](https://reader035.fdocuments.us/reader035/viewer/2022062516/56649daf5503460f94a9ce0c/html5/thumbnails/24.jpg)
SF-6D
1.Physical functioning2.Role limitations3.Social functioning4.Pain5.Mental health6.Vitality
![Page 25: Assessing Health and Economic Outcomes William C. Black, M.D. Director ACRIN Outcomes & Economics Core Laboratory Dartmouth-Hitchcock Medical Center.](https://reader035.fdocuments.us/reader035/viewer/2022062516/56649daf5503460f94a9ce0c/html5/thumbnails/25.jpg)
SF-6D Utility ScoringPhysical Functioning
Term Score
PF1 -0.000
PF2 -0.053
PF3 -0.011
PF4 -0.040
PF5 -0.054
PF6 -0.111
Brazier et al. J Health Econ 2002;21:271-92.
U = 1.000 + ∑Score – 0.070
![Page 26: Assessing Health and Economic Outcomes William C. Black, M.D. Director ACRIN Outcomes & Economics Core Laboratory Dartmouth-Hitchcock Medical Center.](https://reader035.fdocuments.us/reader035/viewer/2022062516/56649daf5503460f94a9ce0c/html5/thumbnails/26.jpg)
• Measure of patient utility
• Measured on a scale of 0-1.0
• Can be assessed directly or
derived from health survey,
e.g., SF-36
Quality Adjusted Life Year
![Page 27: Assessing Health and Economic Outcomes William C. Black, M.D. Director ACRIN Outcomes & Economics Core Laboratory Dartmouth-Hitchcock Medical Center.](https://reader035.fdocuments.us/reader035/viewer/2022062516/56649daf5503460f94a9ce0c/html5/thumbnails/27.jpg)
Quality Adjusted Life Years
0 0.5 1.0
0.5
1.0
Quantity of Life
Qualit
y o
f Li
fe
QALY = 0.5+0.25 = 0.75
![Page 28: Assessing Health and Economic Outcomes William C. Black, M.D. Director ACRIN Outcomes & Economics Core Laboratory Dartmouth-Hitchcock Medical Center.](https://reader035.fdocuments.us/reader035/viewer/2022062516/56649daf5503460f94a9ce0c/html5/thumbnails/28.jpg)
Economic Outcomes
• Direct– inpatient care
– outpatient care
– medications
• Indirect
– time and travel
![Page 29: Assessing Health and Economic Outcomes William C. Black, M.D. Director ACRIN Outcomes & Economics Core Laboratory Dartmouth-Hitchcock Medical Center.](https://reader035.fdocuments.us/reader035/viewer/2022062516/56649daf5503460f94a9ce0c/html5/thumbnails/29.jpg)
Hospitalization Costs
• Triggered by patient questionnaire
• ICD-9, DRGs, and CPTs coded by
MRA
• Medicare reimbursement – Part A MEDPAR
– Part B Physician Fee Schedule
![Page 30: Assessing Health and Economic Outcomes William C. Black, M.D. Director ACRIN Outcomes & Economics Core Laboratory Dartmouth-Hitchcock Medical Center.](https://reader035.fdocuments.us/reader035/viewer/2022062516/56649daf5503460f94a9ce0c/html5/thumbnails/30.jpg)
Outpatient Costs
• Triggered by patient
questionnaire
• ICD-9 and CPTs coded by MRA
• Medicare Physician Fee Schedule
• Red Book avg wholesale prices
![Page 31: Assessing Health and Economic Outcomes William C. Black, M.D. Director ACRIN Outcomes & Economics Core Laboratory Dartmouth-Hitchcock Medical Center.](https://reader035.fdocuments.us/reader035/viewer/2022062516/56649daf5503460f94a9ce0c/html5/thumbnails/31.jpg)
![Page 32: Assessing Health and Economic Outcomes William C. Black, M.D. Director ACRIN Outcomes & Economics Core Laboratory Dartmouth-Hitchcock Medical Center.](https://reader035.fdocuments.us/reader035/viewer/2022062516/56649daf5503460f94a9ce0c/html5/thumbnails/32.jpg)
Indirect Costs
• Triggered by patient
questionnaire
• Travel and other expenses
• Time from usual activities
![Page 33: Assessing Health and Economic Outcomes William C. Black, M.D. Director ACRIN Outcomes & Economics Core Laboratory Dartmouth-Hitchcock Medical Center.](https://reader035.fdocuments.us/reader035/viewer/2022062516/56649daf5503460f94a9ce0c/html5/thumbnails/33.jpg)
CEA
• Societal perspective
• In-trial and lifetime
horizons
• Discounting @ 3%
• Sensitivity analysis
![Page 34: Assessing Health and Economic Outcomes William C. Black, M.D. Director ACRIN Outcomes & Economics Core Laboratory Dartmouth-Hitchcock Medical Center.](https://reader035.fdocuments.us/reader035/viewer/2022062516/56649daf5503460f94a9ce0c/html5/thumbnails/34.jpg)
Incremental Cost Effectiveness
Ratio
∆COSTS
∆QALYSICER =
![Page 35: Assessing Health and Economic Outcomes William C. Black, M.D. Director ACRIN Outcomes & Economics Core Laboratory Dartmouth-Hitchcock Medical Center.](https://reader035.fdocuments.us/reader035/viewer/2022062516/56649daf5503460f94a9ce0c/html5/thumbnails/35.jpg)
c
effect
II IB
IV
IIIA
IA
IIIB
K
Black. Med Decis Making 1990. 10(3): 212-4.
cost
![Page 36: Assessing Health and Economic Outcomes William C. Black, M.D. Director ACRIN Outcomes & Economics Core Laboratory Dartmouth-Hitchcock Medical Center.](https://reader035.fdocuments.us/reader035/viewer/2022062516/56649daf5503460f94a9ce0c/html5/thumbnails/36.jpg)
Comparison
Do Nothing
Do Something
STRATEGY COST QALYS CER
0
$100,000
0
4
NA
$25,000
![Page 37: Assessing Health and Economic Outcomes William C. Black, M.D. Director ACRIN Outcomes & Economics Core Laboratory Dartmouth-Hitchcock Medical Center.](https://reader035.fdocuments.us/reader035/viewer/2022062516/56649daf5503460f94a9ce0c/html5/thumbnails/37.jpg)
Chart Abstraction Process
![Page 38: Assessing Health and Economic Outcomes William C. Black, M.D. Director ACRIN Outcomes & Economics Core Laboratory Dartmouth-Hitchcock Medical Center.](https://reader035.fdocuments.us/reader035/viewer/2022062516/56649daf5503460f94a9ce0c/html5/thumbnails/38.jpg)
Summary
• Variation in practice• Rising costs unsustainable• Radiologic imaging target• “Outcomes” data collection essential• Role of cost-effectiveness analysis